Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ipsen Pharmaceuticals
Biotech
Ipsen inks €1B buyout of French biotech ImCheck
Ipsen is acquiring next-gen immuno-oncology biotech ImCheck for its investigational cancer combo therapy in a deal worth up $1.16 billion.
Gabrielle Masson
Oct 22, 2025 10:33am
Zydus' phase 3 win tees up filing to challenge Gilead and Ipsen
Aug 29, 2025 10:59am
Ipsen hands back Sutro's ROR1 ADC at center of $875M deal
Aug 8, 2025 6:15am
Ipsen joins ADC race via $900M biobuck deal with Sutro
Apr 2, 2024 7:26am
Cell death biotech folds in 'challenging funding environment'
Jul 11, 2023 4:00am
BMS CEO set to leave after 8-year run—Chutes & Ladders
Apr 28, 2023 9:30am
